{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T15:42:56Z","timestamp":1786203776875,"version":"build-2736575974"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00520-026-11062-6","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:50:06Z","timestamp":1785797406000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Symptom burden and symptom clusters in ovarian cancer patients during first-line maintenance therapy: a cross-sectional survey"],"prefix":"10.1007","volume":"34","author":[{"given":"Yi","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bai-lu","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-hang","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-he","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-hua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"11062_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"11062_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26104611","volume":"26","author":"B Smolarz","year":"2025","unstructured":"Smolarz B, Biernacka K, \u0141ukasiewicz H et al (2025) Ovarian cancer-epidemiology, classification, pathogenesis, treatment, and estrogen receptors\u2019 molecular backgrounds. Int J Mol Sci 26:4611. https:\/\/doi.org\/10.3390\/ijms26104611","journal-title":"Int J Mol Sci"},{"key":"11062_CR3","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1001\/jama.2025.9495","volume":"334","author":"G Caruso","year":"2025","unstructured":"Caruso G, Weroha SJ, Cliby W (2025) Ovarian cancer: a review. JAMA 334:1278\u20131291. https:\/\/doi.org\/10.1001\/jama.2025.9495","journal-title":"JAMA"},{"key":"11062_CR4","doi-asserted-by":"publisher","first-page":"972","DOI":"10.6004\/jnccn.2022.0047","volume":"20","author":"DK Armstrong","year":"2022","unstructured":"Armstrong DK, Alvarez RD, Backes FJ et al (2022) NCCN Guidelines\u00ae insights: ovarian cancer, version 3.2022. J Natl Compr Canc Netw 20:972\u2013980. https:\/\/doi.org\/10.6004\/jnccn.2022.0047","journal-title":"J Natl Compr Canc Netw"},{"key":"11062_CR5","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ygyno.2024.01.021","volume":"184","author":"B Pothuri","year":"2024","unstructured":"Pothuri B, Han S, Chase DM et al (2024) Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: results from the phase 3 randomized PRIMA\/ENGOT-OV26\/GOG-3012 trial. Gynecol Oncol 184:168\u2013177. https:\/\/doi.org\/10.1016\/j.ygyno.2024.01.021","journal-title":"Gynecol Oncol"},{"key":"11062_CR6","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","volume":"34","author":"I Ray-Coquard","year":"2023","unstructured":"Ray-Coquard I, Leary A, Pignata S et al (2023) Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial. Ann Oncol 34:681\u2013692. https:\/\/doi.org\/10.1016\/j.annonc.2023.05.005","journal-title":"Ann Oncol"},{"key":"11062_CR7","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.ygyno.2021.05.018","volume":"162","author":"A Alvarez Secord","year":"2021","unstructured":"Alvarez Secord A, O\u2019Malley DM, Sood AK, Westin SN, Liu JF (2021) Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: a review. Gynecol Oncol 162:482\u2013495. https:\/\/doi.org\/10.1016\/j.ygyno.2021.05.018","journal-title":"Gynecol Oncol"},{"key":"11062_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-023-01094-5","volume":"16","author":"Y Wu","year":"2023","unstructured":"Wu Y, Xu S, Cheng S, Yang J, Wang Y (2023) Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status. J Ovarian Res 16:6. https:\/\/doi.org\/10.1186\/s13048-023-01094-5","journal-title":"J Ovarian Res"},{"key":"11062_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijnurstu.2023.104588","volume":"147","author":"Y Li","year":"2023","unstructured":"Li Y, Li J, Hu X (2023) The effectiveness of symptom management interventions based on electronic patient-reported outcomes (ePROs) for symptom burden, quality of life, and overall survival among patients with cancer: a meta-analysis of randomized controlled trials. Int J Nurs Stud 147:104588. https:\/\/doi.org\/10.1016\/j.ijnurstu.2023.104588","journal-title":"Int J Nurs Stud"},{"key":"11062_CR10","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw253","volume":"109","author":"C Miaskowski","year":"2017","unstructured":"Miaskowski C, Barsevick A, Berger A et al (2017) Advancing symptom science through symptom cluster research: expert panel proceedings and recommendations. J Natl Cancer Inst 109:djw253. https:\/\/doi.org\/10.1093\/jnci\/djw253","journal-title":"J Natl Cancer Inst"},{"key":"11062_CR11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jpainsymman.2005.05.015","volume":"31","author":"AM Barsevick","year":"2006","unstructured":"Barsevick AM, Whitmer K, Nail LM, Beck SL, Dudley WN (2006) Symptom cluster research: conceptual, design, measurement, and analysis issues. J Pain Symptom Manage 31:85\u201395. https:\/\/doi.org\/10.1016\/j.jpainsymman.2005.05.015","journal-title":"J Pain Symptom Manage"},{"key":"11062_CR12","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1007\/s00520-015-2666-0","volume":"23","author":"SM Cutshall","year":"2015","unstructured":"Cutshall SM, Cha SS, Ness SM et al (2015) Symptom burden and integrative medicine in cancer survivorship. Support Care Cancer 23:2989\u20132994. https:\/\/doi.org\/10.1007\/s00520-015-2666-0","journal-title":"Support Care Cancer"},{"key":"11062_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12905-025-04221-0","volume":"26","author":"L Jiarui","year":"2025","unstructured":"Jiarui L, Xia L, Zhe W et al (2025) A longitudinal study of early postoperative symptom cluster trajectories in patients with gynecologic malignancies. BMC Womens Health 26:37. https:\/\/doi.org\/10.1186\/s12905-025-04221-0","journal-title":"BMC Womens Health"},{"key":"11062_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7139","volume":"13","author":"Y Feng","year":"2024","unstructured":"Feng Y, Lin T, Liu X, Guo X, Chen J, Deng X (2024) A longitudinal study of symptom cluster latent profiles in ovarian cancer patients undergoing chemotherapy. Cancer Med 13:e7139. https:\/\/doi.org\/10.1002\/cam4.7139","journal-title":"Cancer Med"},{"key":"11062_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115587","volume":"225","author":"RL Coleman","year":"2025","unstructured":"Coleman RL, Fleming GF, Brady MF et al (2025) Veliparib concomitant with first-line chemotherapy and as maintenance therapy in ovarian cancer: final overall survival and disease-related symptoms results. Eur J Cancer 225:115587. https:\/\/doi.org\/10.1016\/j.ejca.2025.115587","journal-title":"Eur J Cancer"},{"issue":"4","key":"11062_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18040650","volume":"18","author":"R Massobrio","year":"2026","unstructured":"Massobrio R, Attianese D, Testi A et al (2026) Symptom monitoring in ovarian cancer patients treated with PARP inhibitors: agreement between physician- and patient-reported toxicities using PRO-CTCAE. Cancers (Basel) 18(4):650. https:\/\/doi.org\/10.3390\/cancers18040650","journal-title":"Cancers (Basel)"},{"issue":"1","key":"11062_CR17","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2024.35.e3","volume":"35","author":"JH Kim","year":"2023","unstructured":"Kim JH, Lee Y, Kim DY et al (2023) Adherence of PARP inhibitor for frontline maintenance therapy in primary epithelial ovarian cancer: a cross-sectional survey. J Gynecol Oncol 35(1):e3. https:\/\/doi.org\/10.3802\/jgo.2024.35.e3","journal-title":"J Gynecol Oncol"},{"key":"11062_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-023-07802-7","volume":"31","author":"KN Zhou","year":"2023","unstructured":"Zhou KN, Wang Y, Xie Y et al (2023) Symptom burden survey and symptom clusters in patients with cervical cancer: a cross-sectional survey. Support Care Cancer 31:338. https:\/\/doi.org\/10.1007\/s00520-023-07802-7","journal-title":"Support Care Cancer"},{"issue":"1","key":"11062_CR19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/19312458.2017.1396583","volume":"12","author":"S Carpenter","year":"2018","unstructured":"Carpenter S (2018) Ten steps in scale development and reporting: a guide for researchers. Commun Methods Meas 12(1):25\u201344","journal-title":"Commun Methods Meas"},{"key":"11062_CR20","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1007\/s00520-025-09653-w","volume":"33","author":"B Han","year":"2025","unstructured":"Han B, Ren S, Jin J et al (2025) Symptom burden and symptom clusters in patients with breast cancer undergoing endocrine therapy: a cross-sectional survey. Support Care Cancer 33:598. https:\/\/doi.org\/10.1007\/s00520-025-09653-w","journal-title":"Support Care Cancer"},{"key":"11062_CR21","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.ygyno.2013.05.009","volume":"130","author":"MH Sailors","year":"2013","unstructured":"Sailors MH, Bodurka DC, Gning I et al (2013) Validating the M. D. Anderson symptom inventory (MDASI) for use in patients with ovarian cancer. Gynecol Oncol 130:323\u2013328. https:\/\/doi.org\/10.1016\/j.ygyno.2013.05.009","journal-title":"Gynecol Oncol"},{"key":"11062_CR22","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.ygyno.2010.07.009","volume":"119","author":"S Agarwal","year":"2010","unstructured":"Agarwal S, Bodurka DC (2010) Symptom research in gynecologic oncology: a review of available measurement tools. Gynecol Oncol 119:384\u2013389. https:\/\/doi.org\/10.1016\/j.ygyno.2010.07.009","journal-title":"Gynecol Oncol"},{"key":"11062_CR23","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/0959-8049(94)90182-1","volume":"30A","author":"RK Portenoy","year":"1994","unstructured":"Portenoy RK, Thaler HT, Kornblith AB et al (1994) The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer 30A:1326\u20131336. https:\/\/doi.org\/10.1016\/0959-8049(94)90182-1","journal-title":"Eur J Cancer"},{"key":"11062_CR24","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.bulcan.2022.06.011","volume":"109","author":"F Selle","year":"2022","unstructured":"Selle F, Boffa JJ, Etienne G et al (2022) Gestion pratique des inhibiteurs de PARP\u202f: Un consensus national DELPHI [Practical management of PARP inhibitors: A French DELPHI consensus]. Bull Cancer 109:1245\u20131261. https:\/\/doi.org\/10.1016\/j.bulcan.2022.06.011","journal-title":"Bull Cancer"},{"key":"11062_CR25","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","volume":"20","author":"CJ LaFargue","year":"2019","unstructured":"LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL (2019) Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol 20:e15\u2013e28. https:\/\/doi.org\/10.1016\/S1470-2045(18)30786-1","journal-title":"Lancet Oncol"},{"key":"11062_CR26","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3390\/curroncol29010029","volume":"29","author":"A Pagkali","year":"2022","unstructured":"Pagkali A, Mamais I, Michalinos A, Agouridis AP (2022) Safety profile of niraparib as maintenance therapy for ovarian cancer: a systematic review and meta-analysis. Curr Oncol 29:321\u2013336. https:\/\/doi.org\/10.3390\/curroncol29010029","journal-title":"Curr Oncol"},{"key":"11062_CR27","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.1016\/j.ejca.2009.05.030","volume":"45","author":"MA Price","year":"2009","unstructured":"Price MA, Zachariae R, Butow PN et al (2009) Prevalence and predictors of insomnia in women with invasive ovarian cancer: anxiety a major factor. Eur J Cancer 45:3262\u20133270. https:\/\/doi.org\/10.1016\/j.ejca.2009.05.030","journal-title":"Eur J Cancer"},{"issue":"6","key":"11062_CR28","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s10865-023-00422-w","volume":"46","author":"D Coutts-Bain","year":"2023","unstructured":"Coutts-Bain D, Sharpe L, Russell H (2023) Death anxiety predicts fear of cancer recurrence and progression in ovarian cancer patients over and above other cognitive factors. J Behav Med 46(6):1023\u20131031. https:\/\/doi.org\/10.1007\/s10865-023-00422-w","journal-title":"J Behav Med"},{"key":"11062_CR29","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1007\/s00520-025-10148-x","volume":"33","author":"Y Xie","year":"2025","unstructured":"Xie Y, Yang SH, Liu SY et al (2025) Characteristics and associated factors of insomnia in gynecological cancer patients: A cross-sectional study. Support Care Cance 33:1092. https:\/\/doi.org\/10.1007\/s00520-025-10148-x","journal-title":"Support Care Cance"},{"key":"11062_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2023.101774","volume":"38","author":"K Koysombat","year":"2024","unstructured":"Koysombat K, McGown P, Nyunt S, Abbara A, Dhillo WS (2024) New advances in menopause symptom management. Best Pract Res Clin Endocrinol Metab 38:101774. https:\/\/doi.org\/10.1016\/j.beem.2023.101774","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"11062_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103984","volume":"9","author":"V Tuninetti","year":"2024","unstructured":"Tuninetti V, Mar\u00edn-Jim\u00e9nez JA, Valabrega G, Ghisoni E (2024) Long-term outcomes of PARP inhibitors in ovarian cancer: survival, adverse events, and post-progression insights. ESMO Open 9:103984. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103984","journal-title":"ESMO Open"},{"key":"11062_CR32","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1136\/ijgc-2022-004079","volume":"33","author":"BJ Monk","year":"2023","unstructured":"Monk BJ, Gonz\u00e1lez-Martin A, Buckley L et al (2023) Safety and management of niraparib monotherapy in ovarian cancer clinical trials. Int J Gynecol Cancer 33:971\u2013981. https:\/\/doi.org\/10.1136\/ijgc-2022-004079","journal-title":"Int J Gynecol Cancer"},{"key":"11062_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102945","volume":"137","author":"BJ Monk","year":"2025","unstructured":"Monk BJ, Lorusso D, Fujiwara K, Sehouli J (2025) Optimal bevacizumab treatment strategy in advanced ovarian cancer: a review. Cancer Treat Rev 137:102945. https:\/\/doi.org\/10.1016\/j.ctrv.2025.102945","journal-title":"Cancer Treat Rev"},{"key":"11062_CR34","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.006278","volume":"6","author":"M Totzeck","year":"2017","unstructured":"Totzeck M, Mincu RI, Rassaf T (2017) Cardiovascular adverse events in patients with cancer treated with bevacizumab: a meta-analysis of more than 20 000 patients. J Am Heart Assoc 6:e006278. https:\/\/doi.org\/10.1161\/JAHA.117.006278","journal-title":"J Am Heart Assoc"},{"key":"11062_CR35","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11886-018-1010-y","volume":"20","author":"BGT Coumbe","year":"2018","unstructured":"Coumbe BGT, Groarke JD (2018) Cardiovascular autonomic dysfunction in patients with cancer. Curr Cardiol Rep 20:69. https:\/\/doi.org\/10.1007\/s11886-018-1010-y","journal-title":"Curr Cardiol Rep"},{"key":"11062_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1304303","volume":"13","author":"I Romero","year":"2024","unstructured":"Romero I, Guerra E, Madariaga A, Manso L (2024) Safety of bevacizumab and olaparib as frontline maintenance therapy in advanced ovarian cancer: expert review for clinical practice. Front Oncol 13:1304303. https:\/\/doi.org\/10.3389\/fonc.2023.1304303","journal-title":"Front Oncol"},{"key":"11062_CR37","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1136\/ijgc-2020-001540","volume":"31","author":"J Ventriglia","year":"2021","unstructured":"Ventriglia J, Paciolla I, Pisano C et al (2021) Arthralgia in patients with ovarian cancer treated with bevacizumab and chemotherapy. Int J Gynecol Cancer 31:110\u2013113. https:\/\/doi.org\/10.1136\/ijgc-2020-001540","journal-title":"Int J Gynecol Cancer"},{"key":"11062_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00426","volume":"10","author":"SP Lee","year":"2019","unstructured":"Lee SP, Hsu HC, Tai YJ et al (2019) Bevacizumab dose affects the severity of adverse events in gynecologic malignancies. Front Pharmacol 10:426. https:\/\/doi.org\/10.3389\/fphar.2019.00426","journal-title":"Front Pharmacol"},{"key":"11062_CR39","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s11912-023-01413-5","volume":"25","author":"S Christensen Holz","year":"2023","unstructured":"Christensen Holz S (2023) Aromatase inhibitor musculoskeletal syndrome and bone loss: a review of the current literature. Curr Oncol Rep 25:825\u2013831. https:\/\/doi.org\/10.1007\/s11912-023-01413-5","journal-title":"Curr Oncol Rep"},{"key":"11062_CR40","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1002\/ijc.34791","volume":"154","author":"ME Schmidt","year":"2024","unstructured":"Schmidt ME, Maurer T, Behrens S et al (2024) Cancer-related fatigue: towards a more targeted approach based on classification by biomarkers and psychological factors. Int J Cancer 154:1011\u20131018. https:\/\/doi.org\/10.1002\/ijc.34791","journal-title":"Int J Cancer"},{"key":"11062_CR41","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrclinonc.2014.127","volume":"11","author":"JE Bower","year":"2014","unstructured":"Bower JE (2014) Cancer-related fatigue\u2013mechanisms, risk factors, and treatments. Nat Rev Clin Oncol 11:597\u2013609. https:\/\/doi.org\/10.1038\/nrclinonc.2014.127","journal-title":"Nat Rev Clin Oncol"},{"key":"11062_CR42","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2025.36.e17","volume":"36","author":"Y Tang","year":"2025","unstructured":"Tang Y, Zhang YY, Wen MB et al (2025) Patient-reported symptom burden and circulating cytokines undergoing chemotherapy: a pilot study in patients with ovarian cancer. J Gynecol Oncol 36:e17. https:\/\/doi.org\/10.3802\/jgo.2025.36.e17","journal-title":"J Gynecol Oncol"},{"key":"11062_CR43","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1097\/jnr.0000000000000478","volume":"30","author":"X Dan","year":"2022","unstructured":"Dan X, Tian Y, Zhou L, Du J, He Y (2022) Longitudinal change in symptom clusters in patients with ovarian cancer. J Nurs Res 30:e196. https:\/\/doi.org\/10.1097\/jnr.0000000000000478","journal-title":"J Nurs Res"},{"key":"11062_CR44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/smi.2972","volume":"37","author":"S Baziliansky","year":"2021","unstructured":"Baziliansky S, Cohen M (2021) Emotion regulation and psychological distress in cancer survivors: a systematic review and meta-analysis. Stress Health 37:3\u201318. https:\/\/doi.org\/10.1002\/smi.2972","journal-title":"Stress Health"},{"key":"11062_CR45","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/npp.2011.205","volume":"37","author":"E Haroon","year":"2012","unstructured":"Haroon E, Raison CL, Miller AH (2012) Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology (New York, NY) 37:137\u2013162. https:\/\/doi.org\/10.1038\/npp.2011.205","journal-title":"Neuropsychopharmacology (New York, NY)"},{"key":"11062_CR46","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.3233\/THC-230735","volume":"32","author":"W Mao","year":"2024","unstructured":"Mao W, Chen W, Wang Y (2024) Effect of virtual reality-based mindfulness training model on anxiety, depression, and cancer-related fatigue in ovarian cancer patients during chemotherapy. Technol Health Care 32:1135\u20131148. https:\/\/doi.org\/10.3233\/THC-230735","journal-title":"Technol Health Care"},{"key":"11062_CR47","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1097\/NCC.0000000000000252","volume":"39","author":"J Huang","year":"2016","unstructured":"Huang J, Gu L, Zhang L, Lu X, Zhuang W, Yang Y (2016) Symptom clusters in ovarian cancer patients with chemotherapy after surgery: a longitudinal survey. Cancer Nurs 39:106\u2013116. https:\/\/doi.org\/10.1097\/NCC.0000000000000252","journal-title":"Cancer Nurs"},{"key":"11062_CR48","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1080\/0167482X.2017.1291624","volume":"38","author":"K Weidner","year":"2017","unstructured":"Weidner K, Croy I, Siepmann T, Br\u00e4hler E, Beutel M, Bittner A (2017) Menopausal syndrome limited to hot flushes and sweating a representative survey study. J Psychosom Obstet Gynaecol 38:170\u2013179. https:\/\/doi.org\/10.1080\/0167482X.2017.1291624","journal-title":"J Psychosom Obstet Gynaecol"},{"key":"11062_CR49","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1136\/ijgc-2020-002032","volume":"31","author":"A Brennan","year":"2021","unstructured":"Brennan A, Brennan D, Rees M, Hickey M (2021) Management of menopausal symptoms and ovarian function preservation in women with gynecological cancer. Int J Gynecol Cancer 31:352\u2013359. https:\/\/doi.org\/10.1136\/ijgc-2020-002032","journal-title":"Int J Gynecol Cancer"},{"key":"11062_CR50","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkae114","volume":"9","author":"F Joly","year":"2025","unstructured":"Joly F, Bazan F, Garbay D et al (2025) Improving real-world evaluation of patient- and physician-reported tolerability: niraparib for recurrent ovarian cancer (NiQoLe). JNCI Cancer Spectr 9:pkae114. https:\/\/doi.org\/10.1093\/jncics\/pkae114","journal-title":"JNCI Cancer Spectr"},{"key":"11062_CR51","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.ygyno.2014.09.016","volume":"135","author":"NP Ezendam","year":"2014","unstructured":"Ezendam NP, Pijlman B, Bhugwandass C et al (2014) Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: results from the population-based PROFILES registry. Gynecol Oncol 135:510\u2013517. https:\/\/doi.org\/10.1016\/j.ygyno.2014.09.016","journal-title":"Gynecol Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11062-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-11062-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11062-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T14:55:37Z","timestamp":1786200937000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-11062-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["11062"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-11062-6","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"2 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Informed consent was secured from all individual participants included in this research.","order":1,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided informed consent for the publication of their data.","order":2,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"826"}}